Scancell announces CFO transition

2 April 2026

Scancell Holdings plc

Scancell announces CFO transition

David Schilansky to be appointed as financial advisor and interim CFO, bringing extensive industry and financial experience, including leading IPOs on Nasdaq and Euronext

Ensures continuity as Scancell advances iSCIB1+ Phase 3 trial and builds shareholder value

Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces David Schilansky, a highly experienced senior healthcare executive and entrepreneur, and Entrepreneur-in-Residence with Redmile Group, has been appointed (with immediate effect) to serve as a financial advisor and shall become interim Chief Financial Officer (CFO) later in April. Current CFO Sath Nirmalananthan has indicated he will be leaving the Company and will step down from the Board of Directors as of April 24, 2026 to pursue other professional opportunities.  Scancell has launched a global recruitment process for a permanent CFO.

Dr Phil L'Huillier, CEO of Scancell, said: "David brings broad and strategic financing expertise to Scancell and will be a strong interim CFO, ensuring continuity and progress in our strategy. We remain laser focused on delivering iSCIB1+ to patients and building shareholder value. Having David in place enables us to seamlessly advance our constructive financing and partnering discussions on our lead ImmunoBody® iSCIB1+, now with the recently obtained strong regulatory feedback in hand. Further, David brings valuable investor engagement and strategic financing expertise, including Nasdaq listing experience that will help guide the company as we explore a potential listing in the US."

Phil L'Huillier added: "Sath has played an important role at Scancell, providing strong financial guidance and preparing us for our next phase of development. On behalf of the Scancell team, I would like to thank Sath for his dedicated and committed efforts to Scancell. We wish him all the best in his future endeavours."

David Schilansky is a seasoned pharma and biotech executive and is currently concluding his role as Chief Executive Officer of Ariceum Therapeutics and commencing as Venture Partner and Entrepreneur-in-Residence at Redmile Group. He was previously CEO and co-founder of Home Biosciences from 2020 to 2025, which created three biotech companies (One Biosciences, Sequantrix and Apikal Therapeutics). From 2011 to 2019, he co-headed DBV Technologies, leading its IPOs on Nasdaq and Euronext, raising a total of more than $1 billion. Prior to that, he held several leadership roles in finance, including Group CFO at Ipsen.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

For more information please contact: